DOP2012000077A - Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina - Google Patents

Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Info

Publication number
DOP2012000077A
DOP2012000077A DO2012000077A DO2012000077A DOP2012000077A DO P2012000077 A DOP2012000077 A DO P2012000077A DO 2012000077 A DO2012000077 A DO 2012000077A DO 2012000077 A DO2012000077 A DO 2012000077A DO P2012000077 A DOP2012000077 A DO P2012000077A
Authority
DO
Dominican Republic
Prior art keywords
ceftaroline
compositions
methods
bacterial infections
treat bacterial
Prior art date
Application number
DO2012000077A
Other languages
English (en)
Inventor
Dirk Thye
George Talbot
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43757152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2012000077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2012000077A publication Critical patent/DOP2012000077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo) y métodos para tratar infecciones bacterianas, tales como ¡nfecciones complicadas de la piel y sus estructuras (CSSSI), y !a neumonía bacteriana adquirida en la comunidad (NBAC), administrando ceftarolina o un profármaco de esta (p. ej., ceftarolina fosamilo).
DO2012000077A 2009-09-21 2012-03-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina DOP2012000077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24412009P 2009-09-21 2009-09-21
US29490110P 2010-01-14 2010-01-14

Publications (1)

Publication Number Publication Date
DOP2012000077A true DOP2012000077A (es) 2012-05-31

Family

ID=43757152

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000077A DOP2012000077A (es) 2009-09-21 2012-03-21 Composiciones y metodos para tratar infecciones bacterianas utilizando ceftarolina

Country Status (24)

Country Link
US (2) US20110071114A1 (es)
EP (1) EP2480236A4 (es)
KR (1) KR20120083344A (es)
CN (1) CN102781451A (es)
AU (1) AU2010295269B2 (es)
BR (1) BR112012006250B1 (es)
CA (1) CA2774772A1 (es)
CL (1) CL2012000694A1 (es)
CO (1) CO6531417A2 (es)
CR (1) CR20120137A (es)
CU (1) CU20120048A7 (es)
DO (1) DOP2012000077A (es)
EA (1) EA029149B1 (es)
EC (1) ECSP12011739A (es)
GT (1) GT201200082A (es)
HN (1) HN2012000585A (es)
IL (1) IL218349A0 (es)
MX (2) MX2012003201A (es)
NI (1) NI201200045A (es)
PE (2) PE20121819A1 (es)
PH (1) PH12012500528A1 (es)
SG (1) SG178936A1 (es)
WO (1) WO2011035305A1 (es)
ZA (1) ZA201202924B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2951171A1 (fr) * 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
US8829191B2 (en) 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
CN107621512B (zh) * 2017-11-02 2020-07-31 扬子江药业集团有限公司 一种柱前衍生化法测定头孢洛林酯侧链酰氯纯度的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW473479B (en) * 1997-12-19 2002-01-21 Takeda Chemical Industries Ltd Phosphonocephem derivatives, their production and use
PT1310502E (pt) * 2000-08-10 2009-07-31 Takeda Pharmaceutical Composto de fosfonocefem
WO2002093162A2 (en) * 2001-05-17 2002-11-21 Mcgill University Individualization of therapy with antibiotic agents
EP2316468A1 (en) * 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
AU2008302201A1 (en) * 2007-09-21 2009-03-26 Astrazeneca Ab Soluble dosage forms containing cephem derivatives suitable for parenteral administration

Also Published As

Publication number Publication date
MX2012003201A (es) 2012-05-08
AU2010295269A1 (en) 2012-04-12
NI201200045A (es) 2012-11-02
KR20120083344A (ko) 2012-07-25
CA2774772A1 (en) 2011-03-24
IL218349A0 (en) 2012-04-30
EP2480236A1 (en) 2012-08-01
ECSP12011739A (es) 2012-05-30
US20150258126A1 (en) 2015-09-17
CU20120048A7 (es) 2012-10-15
ZA201202924B (en) 2012-12-27
AU2010295269B2 (en) 2014-06-05
WO2011035305A1 (en) 2011-03-24
EA029149B1 (ru) 2018-02-28
BR112012006250A2 (pt) 2016-05-31
MX2012003411A (es) 2012-04-30
CN102781451A (zh) 2012-11-14
PE20171176A1 (es) 2017-08-22
PH12012500528A1 (en) 2019-06-14
CL2012000694A1 (es) 2012-08-31
US9629861B2 (en) 2017-04-25
EP2480236A4 (en) 2013-04-17
PE20121819A1 (es) 2013-02-01
HN2012000585A (es) 2015-06-15
SG178936A1 (en) 2012-04-27
US20110071114A1 (en) 2011-03-24
CR20120137A (es) 2012-05-28
CO6531417A2 (es) 2012-09-28
EA201200501A1 (ru) 2012-10-30
BR112012006250B1 (pt) 2021-07-06
GT201200082A (es) 2014-12-22

Similar Documents

Publication Publication Date Title
CR20120264A (es) Compuestos
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
MX2019003738A (es) Compuestos antivirales.
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
CL2013002517A1 (es) Compuestos derivados de fosforoamidato de 5-fluoro-2'-desoxiuridina; procedimiento de preparacion; composicion farmaceutica que los comprende; su uso en el tratamiento o profilaxis del cancer.
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
EA201170832A1 (ru) Пуриновые соединения
MX391043B (es) Formulaciones de anticuerpo y metodos.
MX2011009847A (es) Agentes antihelminticos y su uso.
PA8842101A1 (es) Heteroarilos sustituidos
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
PA8855001A1 (es) Monocarbamas
ECSP11011486A (es) Producción de hidrocarburos de isopreno mejorada que usa citanobacterias diseñadas geneticamente
BR112015009301A2 (pt) biocontrole de nematoides
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
MX2010008852A (es) Formulaciones de flibanserina.
BR112012026542A2 (pt) abordagem seletiva de tecido
CR10467A (es) Profarmacos de penem
DOP2019000102A (es) Constructos de vacuna y sus usos contra infecciones causadas por staphylococcus
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos
BR112014009760A8 (pt) análogos de ácido siálico
CU20120048A7 (es) Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina